Very Long Chain Acyl-CoA Dehydrogenase Deficiency, Gene Mutation Analysis
Very long chain fatty acids acyl-CoA dehydrogenase (VLCAD) is encoded by the ACADVL gene located on the short arm of chromosome 17 and is responsible for the oxidation of long-chain fatty acids (C14 to C20). Mutations in the ACADVL gene may lead to defective production of VLCAD resulting in impaired oxidation of long-chain fatty acids. As a consequence, long-chain fatty acids are not properly utilized for the generation of cellular energy resulting in lethargy and hypoglycemia. Additionally, long-chain fatty acids accumulate in cells, particularly in the heart, liver, and muscles.
VLCAD deficiency is an autosomal recessive disorder with an incidence rate of 1 in 40,000 to 120,000 births and there are three distinct phenotypes of the disease. Individuals with the early-onset type present with cardiomyopathy, cardiac arrest, hypoglycemia, and other hepatic dysfunction. These patients typically deteriorate rapidly and die at a young age. Individuals with the early-childhood onset type present with hypoketotic hypoglycemia and hepatomegaly with or without cardiomyopathy. Late-onset type is a mild form and generally manifests in adolescents or adults with muscle weakness, and/or pain without cardiac or hepatic involvement.
Routine laboratory testing during acute episodes may reveal hypoketotic hypoglycemia and increased creatine kinase and transaminase activities. Individuals with findings suggestive of VLCAD deficiency can be further investigated with plasma acylcarnitine, plasma fatty acids profile, urine organic acids and fibroblast fatty acids oxidation probe test. VLCAD gene mutation analysis can provide a definitive diagnosis of the VLCAD deficiency. Children born with VLCAD deficiency have increase C14:1 carnitine concentration that can be identified during newborn screening. Therefore, all infants with increased C14:1 carnitine in the newborn screening should be confirmed by VLCAD gene mutation analysis.
- Useful to confirm the diagnosis of very long chain acyl-coA dehydrogenase deficiency
- Useful in screening in individuals with family history of very long chain acyl-coA dehydrogenase deficiency deficiency
- To confirm diagnosis in newborn with abnormal screen suggestive of very long chain acyl-coA dehydrogenase deficiency deficiency
Positive for mutation is consistent with very long chain acyl-coA dehydrogenase deficiency deficiency.
No pathogenic variants or mutations detected (Negative for mutations analyzed)
Polymerase chain reaction (PCR) with DNA sequencing analysis, Real-time polymerase chain reaction (PCR), allele specific primer extension (ARMS).
Whole blood (EDTA, Heparin), Amniotic fluid.
Stability
- Ambient: 48 hours
- Refrigerated: 7 days
- Frozen: unacceptable
- J Inherit Metab Dis. 2018;41(6):1169-1178. [PMID: 30194637]
- Mol Genet Metab. 2016;118(4):282-7. [PMID: 27246109]
- Mol Genet Metab. 2006;88(2):166-70. [PMID: 16488171]
- J Pediatr. 2003;143(3):335-42. [PMID: 14517516]
- Hum Mutat. 2001;18(3):169-89. [PMID: 11524729]
- Am J Hum Genet. 1999;64(2):479-94. [PMID: 9973285]